Arkolith/Funds/Affinity Asset Advisors, LLC

Affinity Asset Advisors, LLC

CIK 1773195
Holdings as of Mar 31, 2026·disclosed May 14, 2026·~44-day 13F lag·13F-HR
Inactive

Affinity Asset Advisors, LLC holds a diversified book of 93 stocks worth $1.7B as of Q1 2026 (disclosed May 14, 2026, a ~45-day 13F lag). This quarter they opened HELIX ACQUISITION CORP III and trimmed SPYRE THERAPEUTICS INC. Their largest long position is APOGEE THERAPEUTICS INC at 6% of the equity book. They also disclosed $149.4M in put options (a bearish bet) and $81.9M in call options (bullish), shown separately below and excluded from the equity book.

Build

Build on this 13F portfolio

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.

13F holdings API

Owners, holdings, deltas, point-in-time portfolios.

stock.owners

Form 4 insider API

Open-market buys and sells, cluster scans, company flows.

insider.transactions

MCP quickstart

Connect an agent, mint a key, make the first call.

/api/mcp
Build

Ask your agent what Affinity Asset Advisors, LLC owns

This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.

Get a key Compare plans13F data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/funds/1773195/holdings"
Ask your agent
Use Arkolith to show Affinity Asset Advisors, LLC's latest
holdings, largest changes, and filing provenance.
Opened
18
new positions
Added to
32
existing
Trimmed
25
reduced
Sold out
9
exited

Concentration

Top-heavy: diversified book

Top 5 holdings
26%
Top 10 holdings
42%
Top 20 holdings
64%

Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.

Direct sector allocation

31% mapped to company sectors

ETF / fund or unclassified
69%
Health Care
30%
Financials
0%

Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.

Biggest moves: latest quarter

Estimated $ traded · quarter-end prices, no cost basis

Bought
  • CENTESSA PHARMACEUTICALS PLC
    ▲+133%$31.8M
  • COGENT BIOSCIENCES INC
    ▲+474%$30.9M
  • ROIVANT SCIENCES LTD
    ▲+65%$30.5M
  • ANAPTYSBIO INC
    ▲+111%$27.5M
  • XENON PHARMACEUTICALS INCXENE
    ▲+34%$24.7M
  • ERASCA INCERAS
    ▲+37%$23.5M
Trimmed / exited
  • TRAVERE THERAPEUTICS INCTVTX 2.25 03/01/29
    ▼−96%$208.0M
  • ARCELLX INC
    ▼−31%$18.5M
  • CULLINAN THERAPEUTICS INC
    ▼−60%$16.4M
  • ORUKA THERAPEUTICS INCORKA
    ▼−38%$14.8M
  • BRIDGEBIO PHARMA INC
    ▼−53%$12.6M
  • ABIVAX SA
    ▼−20%$11.1M

Holdings: largest first

Bars show each stock's share of the portfolio. Click a row for its position history.

95 positions
#SecurityValueShares% PortLast moveHistory
1Apogee Therapeutics Inc
COM
$108.2M1.28M
6.3%
▲+4.0%
Added · +50K sh
2Xenon Pharmaceuticals Inc
COM
$97.4M1.68M
5.7%
▲+34%
Added · +425K sh
3Erasca Inc
COM
$86.6M5.35M
5.1%
▲+37%
Added · +1.4M sh
4Insmed Inc
COM PAR $.01
$78.5M480.0K
4.6%
▲+6.7%
Added · +30K sh
5Roivant Sciences Ltd
SHS
$77.6M2.80M
4.5%
▲+65%
Added · +1.1M sh
6Spyre Therapeutics Inc
COM NEW
$64.5M1.28M
3.8%
▼−11%
Reduced · −153K sh
7Centessa Pharmaceuticals PLC
SPONSORED ADS
$55.6M1.40M
3.3%
▲+133%
Added · +799K sh
8Praxis Precision Medicines I
COM NEW
$54.8M170.0K
3.2%
▼−8.1%
Reduced · −15K sh
9Anaptysbio Inc
COM
$52.1M940.0K
3.1%
▲+111%
Added · +495K sh
10Alkermes PLC
SHS
$47.7M1.35M
2.8%
▲+35%
Added · +350K sh
11Cytokinetics Inc
COM NEW
$46.2M700.5K
2.7%
▼−12%
Reduced · −100K sh
12Abivax Sa
SPONSORED ADS
$45.1M405.0K
2.6%
▼−20%
Reduced · −100K sh
13Teva Pharmaceutical Inds Ltd
SPONSORED ADS
$42.2M1.40M
2.5%
—Held
14Arcellx Inc
COMMON STOCK
$41.7M362.8K
2.4%
▼−31%
Reduced · −161K sh
15Nuvalent Inc
COM
$30.7M300.0K
1.8%
▼−7.0%
Reduced · −23K sh
16Terns Pharmaceuticals Inc
COM
$29.7M562.6K
1.7%
▲+2.3%
Added · +13K sh
17Dianthus Therapeutics Inc
COM
$29.4M350.0K
1.7%
▲+204%
Added · +235K sh
18Lexeo Therapeutics Inc
COM
$29.0M5.05M
1.7%
▲+58%
Added · +1.9M sh
19Cogent Biosciences Inc
COM
$28.9M750.0K
1.7%
▲+114%
Added · +400K sh
20Madrigal Pharmaceuticals Inc
COM
$28.8M55.0K
1.7%
▲+77%
Added · +24K sh
21Sutro Biopharma Inc
COM SHS
$26.6M1.07M
1.6%
▲+43%
Added · +321K sh
22Forte Biosciences Inc
COM NEW
$26.2M1.01M
1.5%
▲+2.3%
Added · +22K sh
23Oruka Therapeutics Inc
COM
$24.5M499.7K
1.4%
▼−38%
Reduced · −303K sh
24Trevi Therapeutics Inc
COM
$23.9M2.00M
1.4%
▼−7.0%
Reduced · −150K sh
25Ovid Therapeutics Inc
COM
$23.6M10.64M
1.4%
▲+49%
Added · +3.5M sh
26Enliven Therapeutics Inc
COM
$23.0M586.9K
1.3%
▲Added
Added · +587K sh
27Ascendis Pharma A/s
SPONSORED ADR
$21.7M95.0K
1.3%
▲+217%
Added · +65K sh
28Mineralys Therapeutics Inc
COM
$20.3M750.0K
1.2%
▲+2.7%
Added · +20K sh
29Avalo Therapeutics Inc
COM NEW
$20.0M1.34M
1.2%
▲+28%
Added · +290K sh
30Protagonist Therapeutics Inc
COM
$18.1M172.1K
1.1%
—Held
31Celldex Therapeutics Inc New
COM NEW
$15.9M500.0K
0.9%
▲+43%
Added · +150K sh
32Zura Bio Ltd
CLASS A ORD SHS
$15.3M2.56M
0.9%
▲+41%
Added · +751K sh
33Nurix Therapeutics Inc
COM
$15.0M967.6K
0.9%
—Held
34Savara Inc
COM
$13.7M2.51M
0.8%
▼−10%
Reduced · −285K sh
35Omeros Corp
NOTE 9.500% 6/1
$13.2M6.53M
0.8%
—Held
36Perspective Therapeutics Inc
COM NEW
$13.2M3.16M
0.8%
▲11×
Added · +2.9M sh
37Helix Acquisition Corp III
USD CL A ORD SHS
$12.7M1.25M
0.7%
▲New
New position
38Arrowhead Pharmaceuticals In
COM
$12.5M200.0K
0.7%
▲+186%
Added · +130K sh
39Damora Therapeutics Inc
COM NEW
$11.7M450.0K
0.7%
▲New
New position
40Eupraxia Pharmaceuticals Inc
COM
$11.5M1.59M
0.7%
▲+430%
Added · +1.3M sh
41Alto Neuroscience Inc
COM SHS
$11.2M500.0K
0.7%
▲New
New position
42Bridgebio Pharma Inc
COM
$11.1M150.0K
0.7%
▼−53%
Reduced · −170K sh
43Cullinan Therapeutics Inc
COM
$11.1M781.3K
0.7%
▼−60%
Reduced · −1.2M sh
44Belite Bio Inc
SPONSORED ADS
$10.4M65.0K
0.6%
▲+225%
Added · +45K sh
45Wave Life Sciences Ltd
SHS
$10.2M1.40M
0.6%
▼−48%
Reduced · −1.3M sh
46Vera Therapeutics Inc
CL A
$10.1M250.0K
0.6%
—Held
47Tyra Biosciences Inc
COM
$9.9M257.5K
0.6%
▲New
New position
48Revolution Medicines Inc
COM
$9.7M100.0K
0.6%
—Held
49Jade Biosciences Inc
COM NEW
$9.0M640.0K
0.5%
▼−10%
Reduced · −75K sh
50Travere Therapeutics Inc
COM
$8.9M300.0K
0.5%
—Held
Showing 50 of 95 positions

Largest options & derivatives disclosed

Put / call positions from the 13F — totals include every disclosed option leg

Put notional (bearish)$149.4M
Call notional (bullish)$81.9M
TypeUnderlyingNotional valueUnderlying shares
PUT · bearishSS SPDR S&P 500 ETF TRUST-USSPY$130.1M200K
CALL · bullishMODERNA INCMRNA$40.6M800K
CALL · bullishBRISTOL-MYERS SQUIBB CO$18.2M300K
PUT · bearishREVOLUTION MEDICINES INC$9.7M100K
PUT · bearishIMMUNITYBIO INC$9.6M1.3M
CALL · bullishNOVO-NORDISK A/S-SPONS ADRNVO$6.4M175K
CALL · bullishUNIQURE NV$4.9M300K
CALL · bullishDIANTHUS THERAPEUTICS INC$4.2M50K
CALL · bullishCG ONCOLOGY INC$4.1M60K
CALL · bullishCELCUITY INC$3.4M30K

13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.

Filing history

As-of date vs the date the SEC received each filing

QuarterAs ofFiledPositionsValueForm
Q1 2026Mar 31, 2026May 14, 2026105$1.9B13F-HR
Q4 2025Dec 31, 2025Feb 13, 202695$1.8B13F-HR
Q3 2025Sep 30, 2025Nov 13, 202596$1.1B13F-HR
Q2 2025Jun 30, 2025Aug 13, 202591$732.2M13F-HR
Q1 2025Mar 31, 2025May 14, 202598$1.0B13F-HR
Q4 2024Dec 31, 2024Feb 13, 202585$746.0M13F-HR
Q3 2024Sep 30, 2024Nov 13, 202486$732.8M13F-HR
Q2 2024Jun 30, 2024Aug 14, 202498$867.5M13F-HR
Q1 2024Mar 31, 2024May 14, 202495$807.8M13F-HR
Q4 2023Dec 31, 2023Feb 13, 202482$547.5M13F-HR
Q3 2023Sep 30, 2023Nov 14, 202381$355.5M13F-HR
Q2 2023Jun 30, 2023Aug 21, 202370$286.3M13F-HR/A
Q1 2023Mar 31, 2023May 15, 202374$303.0M13F-HR
Q4 2022Dec 31, 2022Feb 13, 202363$255.0M13F-HR
Q3 2022Sep 30, 2022Nov 14, 202264$358.3M13F-HR
Q2 2022Jun 30, 2022Aug 12, 202254$237.2M13F-HR
Q1 2022Mar 31, 2022May 13, 202259$625.0M13F-HR
Q4 2021Dec 31, 2021Feb 11, 202255$275.4M13F-HR
Q3 2021Sep 30, 2021Nov 12, 202173$396.0M13F-HR
Q2 2021Jun 30, 2021Aug 13, 202169$279.3M13F-HR
Q1 2021Mar 31, 2021May 14, 202172$294.5M13F-HR
Q4 2020Dec 31, 2020Feb 12, 202162$188.7M13F-HR
Amended / restated
  • Q2 2023 · filed Aug 14, 202313F-HR · superseded

Data source

Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.